Clinical Trial Update: Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing acolbifene versus low-dose tamoxifen for prevention of breast cancer in high-risk premenopausal women; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hyperplasia of the Breast
• Breast Cancer
• Ductal Carcinoma in Situ
• Lobular Carcinoma in Situ

Drugs mentioned

• Acolbifene (acolbifene)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Atypical Hyperplasia, Breast Carcinoma | Phase 2 | Status: RECRUITING